Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H8FNO2 |
Molecular Weight | 132.1235 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@]1(C[C@H]([18F])C1)C(O)=O
InChI
InChIKey=NTEDWGYJNHZKQW-DGMDOPGDSA-N
InChI=1S/C5H8FNO2/c6-3-1-5(7,2-3)4(8)9/h3H,1-2,7H2,(H,8,9)/t3-,5-/i6-1
Molecular Formula | C5H8FNO2 |
Molecular Weight | 132.1235 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid (also known as Fluciclovine (18F)) was approved under brand name AXUMIN as a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence. Besides, this radioactive compound is used in patients with cervical, ovarian epithelial or endometrial cancers. Fluciclovine F 18 is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells, but as was shown, this compound has a higher affinity for ASCT2 in comparison with other transporters.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q15758|||Q96RL9 Gene ID: 6510.0 Gene Symbol: SLC1A5 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23647854 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | AXUMIN Approved UseAxumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Launch Date2016 |
|||
Diagnostic | AXUMIN Approved UseUnknown |
|||
Diagnostic | AXUMIN Approved UseUnknown |
|||
Diagnostic | AXUMIN Approved UseUnknown |
Sample Use Guides
The recommended dose is 370 MBq (10 mCi) administered as an intravenous bolus injection.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23647854
Kinetic assays for trans-1-amino-3-fluoro-[1-(14)C]cyclobutanecarboxylic acid ([(14)C]FACBC) were performed in Xenopus laevis oocytes over-expressing either ASCT2 or sodium-coupled neutral amino acid transporter 2 (SNAT2), both of which are highly expressed in prostate cancer cells. ASCT2 and SNAT2 transported [14C]FACBC with Michaelis–Menten kinetics Km values of 96.7 ± 45.2 μM and 196.5 ± 19.7 μM, respectively. LAT1 and LAT2 transported [(14)C]FACBC with Michaelis-Menten Km values of 230.4 ± 184.5 μM and 738.5 ± 87.6 μM, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:59:26 GMT 2023
by
admin
on
Fri Dec 15 17:59:26 GMT 2023
|
Record UNII |
38R1Q0L1ZE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
465814
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/15/1472
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
||
|
NCI_THESAURUS |
C390
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
||
|
FDA ORPHAN DRUG |
929022
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
||
|
WHO-ATC |
V09IX12
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
||
|
NCI_THESAURUS |
C2124
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
||
|
NDF-RT |
N0000177914
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DE-44
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
m12012
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
100000165748
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
450601
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
SUB179608
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
CHEMBL3707268
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
134703
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
Fluciclovine (18F)
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
N0000175869
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | Positron Emitting Activity [MoA] | ||
|
222727-39-1
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
C74002
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
38R1Q0L1ZE
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
DTXSID601027796
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
9243
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
C117460
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
DB13146
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
5153
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
1796118
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY | |||
|
38R1Q0L1ZE
Created by
admin on Fri Dec 15 17:59:26 GMT 2023 , Edited by admin on Fri Dec 15 17:59:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
NON-LABELED -> LABELED |
|
||
|
TARGET -> SUBSTRATE |
lEADS TO ACCUMULATION IN TUMOR CELLS IN RELATION TO NORMAL CELLS
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|